MedTrace Logo

Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation

NCT04840992 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 840

Last updated 2023-02-08

No results posted yet for this study

Summary

This study is a randomized, double-blind, placebo-controlled I/II clinical trial, in order to evaluate the safety and immunogenicity of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation in adults 18 years of Age and Older.

Conditions

Interventions

BIOLOGICAL

Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation

Aerogen Solo

BIOLOGICAL

Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

Intramuscular administration

BIOLOGICAL

Placebo for Inhalation

Aerogen Solo

BIOLOGICAL

Placebo

Intramuscular administration

Sponsors & Collaborators

  • Beijing Institute of Biotechnology

    collaborator OTHER

  • Jiangsu Province Centers for Disease Control and Prevention

    collaborator NETWORK

  • CanSino Biologics Inc.

    lead INDUSTRY

Principal Investigators

  • Fengcai Zhu, MSD · Jiangsu Provincal Center for Disease Control and Prevention

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-21
Primary Completion
2022-07-08
Completion
2022-08-09

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04840992 on ClinicalTrials.gov